ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops its product candidates using its Targeted Antibody Payload (TAP) technology.
Social Media Links
REPORT RATINGS
4.8 / 5.0 (246)
ImmunoGen Inc. reports have an aggregate usefulness score of 4.8 based on 246 reviews.